The insider sales are small relative to market cap and involve a director and a CBO, not the CEO/CFO. Monitor for any upcoming material news (e.g., clinical data, partnership) that could explain the timing, but no immediate action warranted.
IMNM drugs
IMNM drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 13 $26.42entry
- T+1 · 3mo ago +2.95%α +3.15% · $27.20
- T+5 · 3mo ago +6.28%α +8.25% · $28.08
- T+20 · 2mo ago −6.62%α −4.88% · $24.67
- T+60 · 11d ago −29.18%α −23.71% · $18.71
Price Chart
How similar events traded
Executive Summary
Two insiders at Immunome sold a total of $2.54M in shares over a week, led by the Chief Business Officer's $2.27M sale. Director Isaac Barchas also sold $264K. While the dollar amount is modest relative to the $3.0B market cap (~0.08%), the cluster includes a C-suite officer selling a large block, which warrants attention.
Key Financial Metrics
Key Facts
- Chief Business Officer Horn Kinney sold 90.6K shares for $2.27M on 2026-08-04.
- Director Isaac Barchas sold 10.1K shares for $264K on 2026-08-10.
- Total insider sales in the cluster: $2.54M, or ~0.08% of market cap.
- The cluster includes a C-suite officer, but insider sales are weak predictors per academic literature.
Financial Impact
Total insider sales of $2.54M represent ~0.08% of the $3.0B market cap, a trivial amount.
Risk Factors
- Insider sales could precede negative news, though the dollar amount is small.
- Stock has been volatile with mixed prior signal outcomes; avoid over-interpreting this cluster.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-IMNM-1786572087189 |
Track record
20 reports on IMNM
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +26.53% at T+60 after the May 28, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $18.39 Now $17.61 −4.24% settles Feb 12
- Nov 9, 20267d ago S-3ASR Neutral 3/10 Entry $18.65 Now $17.61 −5.58% settles Feb 8
- Nov 9, 20267d ago S-3ASR Neutral 3/10 Entry $18.65 Now $17.61 −5.58% settles Feb 8
- Nov 9, 20267d ago 8-K Bearish 5/10 Entry $18.65 Now $17.61 +5.58% settles Feb 8
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $18.21 Now $17.61 −3.29% settles Jan 28
- Oct 16, 20264w ago ANALYST-UPGRADE Bullish 4/10 Entry $16.47 Now $17.61 +6.92% settles Jan 13
- Oct 5, 20266w ago 8-K Bullish 6/10 Entry $21.17 Now $17.61 −16.82% settles Dec 30
- Oct 1, 20266w ago ANALYST-UPGRADE Bearish 4/10 Entry $20.89 Now $17.61 +15.70% settles Dec 28
- Sep 21, 20268w ago ANALYST-UPGRADE Bullish 4/10 Entry $25.07 Now $17.61 −29.76% settles Dec 15
- Aug 12, 202613w ago Insider Cluster Neutral 4/10 Viewing Entry $26.42 to $18.71 Now $17.61 −33.35% ▼ −29.18% −23.71% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers